share_log

Celularity Analyst Ratings

Celularityのアナリスト評価

Benzinga Analyst Ratings ·  2022/08/23 09:38
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/23/2022 114.29% Truist Securities $10 → $6 Maintains Hold
06/22/2022 435.71% HC Wainwright & Co. → $15 Initiates Coverage On → Buy
04/06/2022 Truist Securities Downgrades Buy → Hold
01/28/2022 221.43% Oppenheimer → $9 Initiates Coverage On → Outperform
11/24/2021 221.43% Morgan Stanley → $9 Initiates Coverage On → Equal-Weight
10/19/2021 328.57% Truist Securities → $12 Initiates Coverage On → Buy

Celularity Questions & Answers

What is the target price for Celularity (CELU)?

The latest price target for Celularity (NASDAQ: CELU) was reported by Truist Securities on August 23, 2022. The analyst firm set a price target for $6.00 expecting CELU to rise to within 12 months (a possible 114.29% upside). 6 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Celularity (CELU)?

The latest analyst rating for Celularity (NASDAQ: CELU) was provided by Truist Securities, and Celularity maintained their hold rating.

When is the next analyst rating going to be posted or updated for Celularity (CELU)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celularity, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celularity was filed on August 23, 2022 so you should expect the next rating to be made available sometime around August 23, 2023.

Is the Analyst Rating Celularity (CELU) correct?

While ratings are subjective and will change, the latest Celularity (CELU) rating was a maintained with a price target of $10.00 to $6.00. The current price Celularity (CELU) is trading at is $2.80, which is out of the analyst's predicted range.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする